Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 05, 2018 08:45 ET | Source: Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals to Participate in Upcoming Investment Conferences

PLYMOUTH MEETING, Pa., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the Company will participate in the following upcoming investment conferences:...
January 22, 2018 08:00 ET | Source: Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals' Published Universal Flu Vaccine Data Demonstrates Protective Responses Against All Major, Lethal H1N1 Influenza Viruses From the Last 100 Years in Animal Models

PLYMOUTH MEETING, Pa., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Inovio’s synthetic vaccine approach using a collection of synthetic DNA...
January 17, 2018 08:00 ET | Source: Inovio Pharmaceuticals, Inc.

Inovio’s Co-Founder along with its Lead Antigen Designer Named Among Top 20 Researchers With Most Granted U.S Patents for 2016

PLYMOUTH MEETING, Pa., Jan. 17, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Dr. David B. Weiner, its co-founder; and Dr. Jian Yan, the company’s Lead...
January 09, 2018 08:00 ET | Source: Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals and the Parker Institute for Cancer Immunotherapy Establish Clinical Development Collaboration To Evaluate Novel Cancer Immunotherapy Combinations

Advances development of Inovio’s ASPIRE™ (Antigen SPecific Immune REsponses) immunotherapy platform as a foundation for novel combination regimen approachesEngages the Parker Institute’s extensive...
January 08, 2018 08:00 ET | Source: Inovio Pharmaceuticals, Inc.

Inovio Receives Milestone Payment from MedImmune as MEDI0457 and Checkpoint Inhibitor Combination Trial in Head and Neck Squamous Cell Cancer Advances to Phase 2

PLYMOUTH MEETING, Pa., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today it has received a milestone payment from MedImmune as MEDI0457 (formerly called...
January 02, 2018 08:00 ET | Source: Inovio Pharmaceuticals, Inc.

Inovio Enters License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in Greater China

PLYMOUTH MEETING, Pa., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it entered an amended agreement providing ApolloBio Corporation (NEEQ:430187)...
December 11, 2017 08:00 ET | Source: Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals Promotes Dr. Laurent Humeau to Senior Vice President, Research & Development

PLYMOUTH MEETING, Pa., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has promoted Dr. Laurent Humeau to Senior Vice President, Research & Development, reporting to...
December 06, 2017 08:00 ET | Source: Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals Appoints Wendy Yarno To its Board of Directors

PLYMOUTH MEETING, Pa., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Wendy Yarno has been elected to the company's Board of Directors. Wendy Yarno...
November 29, 2017 08:00 ET | Source: Inovio Pharmaceuticals, Inc.

Inovio’s Further Analysis of VGX-3100 Phase 2b Data Reveals Immune Correlates and Biomarker Signatures That Predicted Clinical Efficacy

PLYMOUTH MEETING, Pa., Nov. 29, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that post-hoc analysis of data generated from its phase 2b trial of VGX-3100...
November 27, 2017 08:00 ET | Source: Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals SynCon® TERT Cancer Immunotherapy Combined with Checkpoint Inhibitor Synergistically Shrinks Tumor and Improves Survival in Preclinical Tumor Model

PLYMOUTH MEETING, Pa., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) demonstrated the synergistic effect of combining Inovio’s TERT (telomerase reverse transcriptase)...